Pharmaceutical

Signal: Illumina under investigation by SEC over $8bn Grail acquisition

Illumina has faced a series of legal challenges to its 2021 acquisition of Grail; regulators allege willful ignorance.

Aug 16, 2023 - 20:00
Signal: Illumina under investigation by SEC over $8bn Grail acquisition
Illumina has faced a series of legal challenges to its 2021 acquisition of Grail; regulators allege willful ignorance.
Read the original article

Tags:

Previous Article

Galecto terminates development for its lead candidate

Next Article

AGC and Asahi partner for clinical drug production in Seattle

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial

STAT+: Pfizer to halt development of its twice-daily or...

Dec 1, 2023

Appeals court upholds limits to abortion pill

Appeals court upholds limits to abortion pill

Aug 17, 2023

NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

May 15, 2024